Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Full-Life Closes $37 Million Series A for Radiopharmaceutical Oncology Products

publication date: May 26, 2022

Shanghai Full-Life Technologies closed a $37 million Series A financing to develop its pipeline of radiopharmaceutical oncology products and radiotechnology production platform. Full-Life's discovery platform includes optimized single domain antibodies, peptides and linkers to radionuclides. It also pairs each development candidate with a theranostic nuclide to generate human PKPD data that guides patient selection before administering its therapeutic medicines. So far, Full-Life has disclosed three major targets, two of which are in IND development. The financing round was led by Sequoia China, together with Yunion Healthcare Ventures, Junson Capital, CD Capital and Kunlun Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital